Goiter, cardiovascular and metabolic disorders in patients with acromegaly

Endocrine Regulations

Volumn 45, Issue 4, 2011, Pages 191-197

  Golkowski, F ^a   Krzentowska Korek, A ^a   Baldys Waligorska, A ^a   Hubalewska Dydejczyk, A ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Acromegaly; Diabetes; Goiter; Growth hormone; Hypertension; IGF 1; Pituitary

Indexed keywords

GLUCOSE; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE DURATION; FEMALE; GLUCOSE INTAKE; GLUCOSE INTOLERANCE; GOITER; GROWTH HORMONE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PROTEIN BLOOD LEVEL; RISK FACTOR;

ACROMEGALY; ADULT; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; GOITER; HUMAN GROWTH HORMONE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN-LIKE GROWTH FACTOR I; MALE; METABOLIC DISEASES; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PREVALENCE; RISK FACTORS;

EID: 83455179377     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: 10.4149/endo_2011_04_191     Document Type: Article

References (34)

1. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS: Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89, 1613-1617, 2004. http://dx.doi.org/10.1210/jc.2003-031584
2. Bałdys-Waligorska A, Golkowski F, Krzentowska A, Sokolowski G, Hubalewska-Dydejczyk A: Evaluation of the efficacy of octreotide LAR in the treatment of acromegaly - a yearly observation. Przegl Lek 66, 218-221, 2009.
3. Biering H, Knappe G, Gerl H, Lochs H: Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca 27, 27-31, 2000. http://dx.doi.org/10.1046/j.1563-2571.2000.00106.x
4. Buhk JH, Jung S, Psychogios MN, Goricke S, Hartz S, Schulz-Heise S, Klingebiel R, Forsting M, Brückmann H, Dörfler A, Jordan M, Buchfelder M, Knauth M: Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 95, 552-558, 2010. http://dx.doi.org/10.1210/jc.2009-1239
5. Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LF, Lombardi G, Pivonello R: Impact of Somatostatin Analogs vs. surgery on glucose metabolism in acromegaly. Results of a 5 years observational, open, prospective study. J Clin Endocrinol Metab 94, 528-537, 2009. http://dx.doi.org/10.1210/jc.2008-1546
6. Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LF, Lombardi G, Savastano S: Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 159, 389-397, 2008. http://dx.doi.org/10.1530/EJE-08-0201
7. Daroszewski J, Bolanowski M, Kaluzny M, Siewinski M: The imbalance of cathepsin B-like activity in acromegalic patients - preliminary report. Neuro Endocrinol Lett 31, 256-260, 2010.
8. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP: Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93, 61-67, 2008. http://dx.doi.org/10.1210/jc.2007-1191
9. Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely AJ: Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 69, 2207-2226, 2009. http://dx.doi.org/10.2165/11318510-000000000-00000
10. Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, Mariotti S, Colao AM, Lombardi G, Baldelli R, Camanni F, Liuzzi A: Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest 25, 240-245, 2002.
11. Ghigo E, Biller BM, Colao A, Kourides IA, Rajicic N, Hutson RK, De Marinis L, Klibanski A: Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. J Endocrinol Invest 32, 924-933, 2009.
12. Herrmann BL, Baumann H, Janssen OE, Görges R, Schmid KW, Mann K: Impact of disease activity on thyroid diseases in patients with acromegaly: basal evaluation and follow-up. Exp Clin Endocrinol Diabetes 112, 225-230, 2004. http://dx.doi.org/10.1055/s-2004-817967
13. Herrmann BL, Severing M, Schmermund A, Berg C, Budde T, Erbel R, Mann K: Impact of disease duration on coronary calcification in patients with acromegaly. Exp Clin Endocrinol Diabetes 117, 417-422, 2009. http://dx.doi.org/10.1055/s-0029-1214386
14. Holdaway IM, Bolland MJ, Gamble GD: A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159, 89-95. 2008. http://dx.doi.org/10.1530/EJE-08-0267
15. Holdaway IM, Rajasoorya RC, Gamble GD: Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89, 667-674, 2004. http://dx.doi.org/10.1210/jc.2003-031199
16. Kasagi K, Shimatsu A, Miyamoto S, Misaki T, Sakahara H, Konishi J: Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Thyroid 9, 791-796, 1999. http://dx.doi.org/10.1089/thy.1999.9.791
17. Kauppinen-Makelin R, Sane T, Reunanen A, Välimäki MJ, Niskanen L, Markkanen H, Löyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E: A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90, 4081-4086, 2005. http://dx.doi.org/10.1210/jc.2004-1381
18. Kreze A, Kreze-Spirova E, Mikulecky M: Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 34, 1429-1433, 2001. http://dx.doi.org/10.1590/S0100-879X2001001100009
19. Krzentowska-Korek A, Golkowski F, Baldys-Waligorska A, Hubalewska-Dydejczyk A: Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary 14, 157-162, 2011. http://dx.doi.org/10.1007/s11102-010-0273-0
20. Kumar SS, Ayuk J, Murray RD: Current therapy and drug pipeline for the treatment of patients with acromegaly. Adv Ther 26, 383-403, 2009. http://dx.doi.org/10.1007/s12325-009-0029-9
21. Kurimoto M, Fukuda I, Hizuka N, Takano K: The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J 55, 67-71, 2008. http://dx.doi.org/10.1507/endocrj.K07E-010
22. Melmed S: Acromegaly pathogenesis and treatment. J Clin Invest 119, 3189-3202, 2009. http://dx.doi.org/10.1172/JCI39375
23. Mustacchi P, Shimkin MB: Occurrence of cancer in acromegaly and in hypopituitarism. Cancer 10, 100-104, 1957. http://dx.doi.org/10.1002/1097-0142(195701/02)10:1100::AID-CNCR28201001133.0.CO;2-V
24. Orme SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly; a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83, 2730-2734, 1998. http://dx.doi.org/10.1210/jc.83.8.2730
25. Ozbey NC, Onccul A, Bugra Z, Vural A, Erzengin F, Orhan Y, Buyukozturk K, Sencer E, Molvaillar S: Acromegalic cardiomyopathy: Evaluation of the left ventricular diastolic function in the subclinical stage. J Endocrinol Invest 20, 305-311, 1997.
26. Rajasoorya C, Holdawey IM, Wrighston P, Scott DJ, Ibbertson HK: Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 42, 95-102, 1994. http://dx.doi.org/10.1111/j.1365-2265.1994.tb03789.x
27. Roug S, Rasmussen AK, Juhler M, Kosteljanetz M, Poulsgaard L, Heeboll H, Roed H, Feldt-Rasmussen U: Fractionated stereotactic radiotherapy in patients wth acromegaly: an interim single-centre audit. Eur J Endocrinol 162, 685-94, 2010.
28. http://dx.doi.org/10.1530/EJE-09-1045
29. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83, 3419-3426, 1998. http://dx.doi.org/10.1210/jc.83.10.3419
30. Tan KC, Shiu SW, Janus ED, Lam KS: LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I. Atherosclerosis 129, 59-65, 1997. http://dx.doi.org/10.1016/S0021-9150(96)06015-7
31. Terzolo M, Reimondo G, Gasperi M, Cozzi R, Pivonello R, Vitale G, Scillitani A, Attanasio R, Cecconi E, Daffara F, Gaia E, Martino E, Lombardi G, Angeli A, Colao A: Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab 90, 84-90, 2005. http://dx.doi.org/10.1210/jc.2004-0240
32. Van Thiel SW, Bax JJ, Biermasz NR, Holman ER, Poldermans D, Roelfsema F, Lamb HJ, van der Wall EE, Smit JW, Romijn JA, Pereira AM: Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. Eur J Endocrinol 153, 231-238, 2005. http://dx.doi.org/10.1530/eje.1.01955
33. Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, Lombardi G, Colao A: Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol. (Oxf) 63, 470-476, 2005. http://dx.doi.org/10.1111/j.1365-2265.2005.02370.x
34. Wuster C, Both S, Cordes U, Omran W, Reisch R: Primary treatment of acromegaly with high-dose lanreotide: a case series. J Med Case Reports 4, 85, 2010. http://dx.doi.org/10.1186/1752-1947-4-85